NCT06378905
Cukurova Score Validation Study
Recruiting · Not specified · Cukurova University · registry updated 2024-08-29
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Despite significant advancements in imaging technologies, surgical techniques, chemotherapeutic regimens, and treatment strategies in recent years, ovarian cancer continues to remain the most deadly gynecological malignancy. Approximately 90% of ovarian cancers originate from the coelomic epithelium or modified mesothelial cells and are classified as epithelial ovarian cancers. The majority of patients with epithelial ovarian cancer (70-80%) present in advanced stages. The primary treatment for advanced-stage (stage 3-4) disease consists of primary cytoreductive surgery followed by adjuvant chemotherapy. Cytoreductive surgery aims to remove all visible tumor implants regardless of the extent of the disease and achieve no visible residual tumor (complete cytoreduction, R0) at the end of the surgery. In cases where R0 cannot be achieved (due to poor general condition and/or extensive tumor that cannot be completely excised surgically), the option of neoadjuvant chemotherapy followed by interval cytoreductive surgery is considered....
Inclusion
- years old and over
- Suspected advanced ovarian/fallopian tube/ primary peritoneal carcinomatosis on imaging
- Pathologically confirmed Stage III-IV epithelial ovarian cancer/fallopian tube/ primary peritoneal carcinomatosis
- Consent to participate in the study
Exclusion
- Stage I-II epithelial ovarian/fallopian tube/peritoneal cancer
- Nonepithelial Ovarian Cancer
- Benign Ovarian tumors
- Borderline Ovarian Tumors
- Metastatic Ovarian Tumors
- Rejecting to Participate in the Study